A bio-clinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.

Mark Bosch, Ariz Akhter, Bingshu E. Chen, Adnan Mansoor, David Lebrun, David Good, Michael Crump, Lois Shepherd, David W. Scott, and Douglas A Stewart

Collaborative Groups: Canadian Cancer Trials Group (Bingshu E Chen, David Good, Michael Crump, Lois Shepherd, David W Scott, Douglas A Stewart)

Disclosures: This work was funded by: Canadian Cancer Society Research Institute grants 021039 and 704970, as well as the Alberta Cancer Foundation (ACF) grants 25987 and 26070. D.W.S is a named inventor on a patent for assigning molecular subtypes for DLBCL which has been licensed by NanoString Technologies

Contributions: M.B, D.S helped with conception and design of the study, collection and assembly of data, data analysis and interpretation, statistical analysis, and manuscript writing; A.M. & A.A. helped with pathology review, collection and assembly of data, data analysis and interpretation, and manuscript writing; D.L. & D.G helped with pathology review and data analysis and interpretation; B.C. provided the statistical analysis, data analysis and interpretation; D.W.S. helped with the FISH testing and interpretation, M.C & L.S. helped with data analysis and interpretation, and the national conduct of this study. All authors gave final approval of manuscript.